Page 1 of 101
NURS 5334 ADVANCED PHARM EXAM PACK 2026
QUESTIONS WITH VERIFIED ANSWERS DETAILED
RATIONALES GRADED A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. The impact of the body on drugs, including how much of an administered dose gets to its
sites of action, is defined as:
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacotherapeutics
D) Pharmacogenomics
Answer: B) Pharmacokinetics
Rationale: Pharmacokinetics refers to the impact of the body on drugs, including absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics refers to the impact of
drugs on the body.
2. Which of the following is NOT one of the four major pharmacokinetic processes?
A) Drug absorption
B) Drug distribution
C) Drug metabolism
D) Drug receptor binding
1|Page
,Page 2 of 101
Answer: D) Drug receptor binding
Rationale: The four major pharmacokinetic processes are drug absorption, drug distribution,
drug metabolism, and drug excretion. Receptor binding is a pharmacodynamic process.
3. A patient with chronic kidney disease (Stage 4) is prescribed a medication that is primarily
renally excreted. The nurse anticipates that the patient will require:
A) A higher dose to achieve a therapeutic effect
B) A lower dose or longer dosing interval to prevent toxicity
C) The same dose as a patient with normal renal function
D) An increased frequency of administration
Answer: B) A lower dose or longer dosing interval to prevent toxicity
Rationale: In renal impairment, drug clearance is reduced, leading to drug accumulation and
increased risk of toxicity. Dose reduction or extended dosing intervals are required.
4. A drug has a half-life of 24 hours. Approximately how many hours will it take for the drug to
reach steady state?
A) 24 hours
B) 48 hours
C) 120 hours
D) 240 hours
Answer: C) 120 hours
Rationale: Steady state is achieved after approximately 4–5 half-lives. With a half-life of 24
hours, 4–5 half-lives equal 96–120 hours.
2|Page
,Page 3 of 101
5. A patient is prescribed a drug that is a weak acid (pKa 4.4). In which part of the
gastrointestinal tract will absorption be most rapid?
A) Mouth (pH 7.0)
B) Stomach (pH 1.5)
C) Duodenum (pH 6.0)
D) Colon (pH 7.5)
Answer: B) Stomach (pH 1.5)
Rationale: Weak acids are best absorbed in acidic environments where they remain non-ionized
(lipid-soluble). In the stomach's acidic pH, the drug is predominantly non-ionized, allowing for
passive diffusion across the gastric mucosa.
6. What is bioavailability?
A) The extent of drug that becomes available to the body after absorption
B) The rate of drug excretion by the kidneys
C) The amount of drug bound to plasma proteins
D) The time it takes for a drug to reach peak plasma concentration
Answer: A) The extent of drug that becomes available to the body after absorption
Rationale: Bioavailability refers to the fraction of an administered dose that reaches systemic
circulation in an unchanged form.
7. What is "free drug"?
A) The drug that is not bound to protein that is free to exert a therapeutic effect
B) The drug that is metabolized by the liver
C) The drug that is excreted by the kidneys
D) The drug that is stored in adipose tissue
3|Page
, Page 4 of 101
Answer: A) The drug that is not bound to protein that is free to exert a therapeutic effect
Rationale: Only unbound (free) drug can cross membranes and interact with target receptors to
produce a pharmacological effect.
8. A patient taking warfarin for atrial fibrillation is newly prescribed rifampin for a
tuberculosis infection. What is the most likely pharmacokinetic interaction the NP should
anticipate?
A) Rifampin will inhibit CYP450 enzymes, leading to warfarin toxicity and bleeding.
B) Rifampin will induce CYP450 enzymes, accelerating warfarin metabolism and decreasing its
therapeutic effect.
C) Rifampin will displace warfarin from plasma proteins, causing an immediate spike in INR.
D) Rifampin will increase warfarin absorption, leading to toxicity.
Answer: B) Rifampin will induce CYP450 enzymes, accelerating warfarin metabolism and
decreasing its therapeutic effect.
Rationale: Rifampin is a potent CYP450 inducer, which speeds up the metabolism of warfarin,
thereby lowering its blood levels and increasing the risk of thromboembolic events.
9. An elderly, malnourished patient with a serum albumin level of 2.5 g/dL is prescribed a
highly protein-bound medication (95% bound). What is the primary clinical concern for this
patient?
A) The drug will be excreted too rapidly, leading to subtherapeutic levels.
B) The drug will have decreased absorption in the gastrointestinal tract.
C) There will be an increase in the free, active fraction of the drug, raising the risk of toxicity.
D) The drug will become completely inactive and fail to produce any therapeutic effect.
Answer: C) There will be an increase in the free, active fraction of the drug, raising the risk of
toxicity.
4|Page
NURS 5334 ADVANCED PHARM EXAM PACK 2026
QUESTIONS WITH VERIFIED ANSWERS DETAILED
RATIONALES GRADED A+
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. The impact of the body on drugs, including how much of an administered dose gets to its
sites of action, is defined as:
A) Pharmacodynamics
B) Pharmacokinetics
C) Pharmacotherapeutics
D) Pharmacogenomics
Answer: B) Pharmacokinetics
Rationale: Pharmacokinetics refers to the impact of the body on drugs, including absorption,
distribution, metabolism, and excretion (ADME). Pharmacodynamics refers to the impact of
drugs on the body.
2. Which of the following is NOT one of the four major pharmacokinetic processes?
A) Drug absorption
B) Drug distribution
C) Drug metabolism
D) Drug receptor binding
1|Page
,Page 2 of 101
Answer: D) Drug receptor binding
Rationale: The four major pharmacokinetic processes are drug absorption, drug distribution,
drug metabolism, and drug excretion. Receptor binding is a pharmacodynamic process.
3. A patient with chronic kidney disease (Stage 4) is prescribed a medication that is primarily
renally excreted. The nurse anticipates that the patient will require:
A) A higher dose to achieve a therapeutic effect
B) A lower dose or longer dosing interval to prevent toxicity
C) The same dose as a patient with normal renal function
D) An increased frequency of administration
Answer: B) A lower dose or longer dosing interval to prevent toxicity
Rationale: In renal impairment, drug clearance is reduced, leading to drug accumulation and
increased risk of toxicity. Dose reduction or extended dosing intervals are required.
4. A drug has a half-life of 24 hours. Approximately how many hours will it take for the drug to
reach steady state?
A) 24 hours
B) 48 hours
C) 120 hours
D) 240 hours
Answer: C) 120 hours
Rationale: Steady state is achieved after approximately 4–5 half-lives. With a half-life of 24
hours, 4–5 half-lives equal 96–120 hours.
2|Page
,Page 3 of 101
5. A patient is prescribed a drug that is a weak acid (pKa 4.4). In which part of the
gastrointestinal tract will absorption be most rapid?
A) Mouth (pH 7.0)
B) Stomach (pH 1.5)
C) Duodenum (pH 6.0)
D) Colon (pH 7.5)
Answer: B) Stomach (pH 1.5)
Rationale: Weak acids are best absorbed in acidic environments where they remain non-ionized
(lipid-soluble). In the stomach's acidic pH, the drug is predominantly non-ionized, allowing for
passive diffusion across the gastric mucosa.
6. What is bioavailability?
A) The extent of drug that becomes available to the body after absorption
B) The rate of drug excretion by the kidneys
C) The amount of drug bound to plasma proteins
D) The time it takes for a drug to reach peak plasma concentration
Answer: A) The extent of drug that becomes available to the body after absorption
Rationale: Bioavailability refers to the fraction of an administered dose that reaches systemic
circulation in an unchanged form.
7. What is "free drug"?
A) The drug that is not bound to protein that is free to exert a therapeutic effect
B) The drug that is metabolized by the liver
C) The drug that is excreted by the kidneys
D) The drug that is stored in adipose tissue
3|Page
, Page 4 of 101
Answer: A) The drug that is not bound to protein that is free to exert a therapeutic effect
Rationale: Only unbound (free) drug can cross membranes and interact with target receptors to
produce a pharmacological effect.
8. A patient taking warfarin for atrial fibrillation is newly prescribed rifampin for a
tuberculosis infection. What is the most likely pharmacokinetic interaction the NP should
anticipate?
A) Rifampin will inhibit CYP450 enzymes, leading to warfarin toxicity and bleeding.
B) Rifampin will induce CYP450 enzymes, accelerating warfarin metabolism and decreasing its
therapeutic effect.
C) Rifampin will displace warfarin from plasma proteins, causing an immediate spike in INR.
D) Rifampin will increase warfarin absorption, leading to toxicity.
Answer: B) Rifampin will induce CYP450 enzymes, accelerating warfarin metabolism and
decreasing its therapeutic effect.
Rationale: Rifampin is a potent CYP450 inducer, which speeds up the metabolism of warfarin,
thereby lowering its blood levels and increasing the risk of thromboembolic events.
9. An elderly, malnourished patient with a serum albumin level of 2.5 g/dL is prescribed a
highly protein-bound medication (95% bound). What is the primary clinical concern for this
patient?
A) The drug will be excreted too rapidly, leading to subtherapeutic levels.
B) The drug will have decreased absorption in the gastrointestinal tract.
C) There will be an increase in the free, active fraction of the drug, raising the risk of toxicity.
D) The drug will become completely inactive and fail to produce any therapeutic effect.
Answer: C) There will be an increase in the free, active fraction of the drug, raising the risk of
toxicity.
4|Page
